Breaking News Instant updates and real-time market news.

KALA

Kala Pharmaceuticals

$7.46

-0.07 (-0.93%)

16:04
04/24/19
04/24
16:04
04/24/19
16:04

Kala Pharmaceuticals initiated with an Outperform at Oppenheimer

Oppenheimer initiated Kala Pharmaceuticals with an Outperform and $11 price target.

  • 15

    Aug

KALA Kala Pharmaceuticals
$7.46

-0.07 (-0.93%)

11/14/18
JPMS
11/14/18
NO CHANGE
Target $22
JPMS
Overweight
Kala Pharmaceuticals selloff an attractive long-term opportunity, says JPMorgan
JPMorgan analyst Chris Schott says the 45% selloff in shares of Kala Pharmaceuticals over the last three months creates an attractive long-term opportunity. The analyst continues to see Kala as an "attractive ophthalmology pure-play" with a third ongoing pivotal Phase 3 trial for KPI-121 in dry eye with top-line results expected in Q4 of 2019 as well as the upcoming launch for the recently approved Inveltys for post-surgical pain and inflammation expected in early 2019. Inveltys offers a "de-risked opportunity" with peak sales potential of several hundred million dollars while KPI-121 represents a potentially more meaningful product, Schott tells investors in a research note. He lowered his price target for Kala Pharmaceuticals to $22 from $35 and keeps an Overweight rating on the name.
03/14/19
JEFF
03/14/19
INITIATION
Target $15
JEFF
Buy
Kala Pharmaceuticals initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Kala Pharmaceuticals with a Buy rating and $15 price target.
03/14/19
JEFF
03/14/19
INITIATION
Target $15
JEFF
Buy
Jefferies starts Kala Pharmaceuticals with Buy rating, $15 price target
Jefferies analyst Biren Amin initiated coverage of Kala Pharmaceuticals with a Buy rating and $15 price target. The company has reformulated loteprednol, an ocular steroid, with mucus-penetrating particles to provide superior penetration versus traditional steroid eye drops, Amin tells investors in a research note. It lead asset Inveltys is launching for use in post-operation surgeries and investors assume a slow launch for a product that could generate $150M in peak sales, the analyst adds. Further, he believes KPI-121 0.25% provides a "second and more meaningful catalyst" with Stride 3 pivotal data in dry eye at year-end 2019.
03/14/19
03/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with an Outperform at Cowen. 2. Fluidigm (FLDM) initiated with a Buy at BTIG. 3. Kala Pharmaceuticals (KALA) initiated with a Buy at Jefferies. 4. PLx Pharma (PLXP) initiated with an Outperform at JMP Securities. 5. Walker & Dunlop (WD) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

07:45
06/26/19
06/26
07:45
06/26/19
07:45
General news
U.S. MBA reported mortgage applications bounced 1.3% »

U.S. MBA reported…

UPWK

Upwork

$15.07

-0.41 (-2.65%)

, FVRR

Fiverr

$29.00

-0.2 (-0.68%)

07:44
06/26/19
06/26
07:44
06/26/19
07:44
Upgrade
Upwork, Fiverr rating change  »

Upwork upgraded to Buy…

UPWK

Upwork

$15.07

-0.41 (-2.65%)

FVRR

Fiverr

$29.00

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LINX

Linx S.A.

$0.00

(0.00%)

07:41
06/26/19
06/26
07:41
06/26/19
07:41
Syndicate
Linx S.A. 32.8M share IPO priced at $9.40 »

We are told the official…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

07:40
06/26/19
06/26
07:40
06/26/19
07:40
General news
Treasury Market Outlook: Treasury yields jumped higher »

Treasury Market Outlook:…

BBRX

Braeburn Pharmaceuticals

$0.00

(0.00%)

07:38
06/26/19
06/26
07:38
06/26/19
07:38
Initiation
Braeburn Pharmaceuticals initiated  »

Braeburn Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FISV

Fiserv

$90.27

-0.53 (-0.58%)

07:38
06/26/19
06/26
07:38
06/26/19
07:38
Upgrade
Fiserv rating change  »

Fiserv upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVSI

Envision Solar

$5.11

-0.22 (-4.13%)

07:38
06/26/19
06/26
07:38
06/26/19
07:38
Initiation
Envision Solar initiated  »

Envision Solar initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$1.66

-0.05 (-2.93%)

07:37
06/26/19
06/26
07:37
06/26/19
07:37
Initiation
Kadmon initiated  »

Oppenheimer bullish on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCR

Novocure

$57.44

-0.58 (-1.00%)

07:37
06/26/19
06/26
07:37
06/26/19
07:37
Hot Stocks
Novocure announces publication of IQWiG rapid report for Optune »

Novocure announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSTR

CapStar Financial

$15.01

0.05 (0.33%)

07:37
06/26/19
06/26
07:37
06/26/19
07:37
Downgrade
CapStar Financial rating change  »

CapStar Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCRX

Pacira

$43.53

0.39 (0.90%)

07:35
06/26/19
06/26
07:35
06/26/19
07:35
Hot Stocks
Pacira says results show EXPAREL associated with 'significantly less' opioid use »

Pacira BioSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ODT

Odonate Therapeutics

$28.14

-0.29 (-1.02%)

07:35
06/26/19
06/26
07:35
06/26/19
07:35
Syndicate
Odonate Therapeutics 4.75M share Spot Secondary priced at $26.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 26

    Jun

X

U.S. Steel

$14.93

0.48 (3.32%)

07:35
06/26/19
06/26
07:35
06/26/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGO

Eldorado Gold

$5.46

-0.02 (-0.36%)

07:34
06/26/19
06/26
07:34
06/26/19
07:34
Upgrade
Eldorado Gold rating change  »

Eldorado Gold upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XON

Intrexon

$7.34

0.17 (2.37%)

07:33
06/26/19
06/26
07:33
06/26/19
07:33
Hot Stocks
Intrexon doses first patient in Phase 1/1b study of Acute Myeloid Leukemia drug »

Intrexon's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOSC

B.O.S. Better Online

$2.73

(0.00%)

07:33
06/26/19
06/26
07:33
06/26/19
07:33
Hot Stocks
B.O.S. Better Online receives $870,000 order for robotic system »

B.O.S Better Online…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRIM

Primoris

$19.57

0.32 (1.66%)

07:32
06/26/19
06/26
07:32
06/26/19
07:32
Hot Stocks
Primoris announces heavy civil award valued over $24M »

Primoris Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$133.43

-4.37 (-3.17%)

, AMZN

Amazon.com

$1,879.26

-34.17 (-1.79%)

07:31
06/26/19
06/26
07:31
06/26/19
07:31
Recommendations
Microsoft, Amazon.com, Oracle analyst commentary at Wedbush »

Pentagon JEDI contract to…

MSFT

Microsoft

$133.43

-4.37 (-3.17%)

AMZN

Amazon.com

$1,879.26

-34.17 (-1.79%)

ORCL

Oracle

$56.07

-0.65 (-1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 06

    Aug

EXTR

Extreme Networks

$5.73

0.08 (1.42%)

07:30
06/26/19
06/26
07:30
06/26/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

DNLI

Denali Therapeutics

$20.22

0.56 (2.85%)

07:29
06/26/19
06/26
07:29
06/26/19
07:29
Initiation
Denali Therapeutics initiated  »

Denali Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRCM

Care.com

$14.13

0.21 (1.51%)

07:28
06/26/19
06/26
07:28
06/26/19
07:28
Recommendations
Care.com analyst commentary  »

Care.com CFO resignation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRCM

Care.com

$14.13

0.21 (1.51%)

07:28
06/26/19
06/26
07:28
06/26/19
07:28
Downgrade
Care.com rating change  »

Care.com downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$48.24

-3.17 (-6.17%)

07:27
06/26/19
06/26
07:27
06/26/19
07:27
Recommendations
Lennar analyst commentary  »

Lennar selloff appears…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

MU

Micron

$32.71

-0.47 (-1.42%)

07:27
06/26/19
06/26
07:27
06/26/19
07:27
Upgrade
Micron rating change  »

Micron upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

AVAV

AeroVironment

07:27
06/26/19
06/26
07:27
06/26/19
07:27
Recommendations
AeroVironment analyst commentary  »

AeroVironment price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.